Famciclovir is relatively safer for which patient group due to its safety profile?

• A. Immunocompetent
• B. Immunocompromised
• C. Pregnant
• D. Children

Answer: (B)

The big idea is safety of antiviral therapy in patients with weakened immune systems. Famciclovir, as a prodrug of penciclovir, provides effective activity against HSV and VZV with a tolerable systemic safety profile. In immunocompromised individuals, avoiding drugs that cause bone marrow suppression or severe systemic toxicity is crucial because their immune defense is already reduced. Favored by its comparatively low risk of hematologic toxicity versus agents like ganciclovir, famciclovir minimizes additional cytopenia while still delivering adequate antiviral effect. This makes it a safer option for treating systemic or disseminated herpetic infections in those with compromised immunity. While data exist for other populations, the relative safety in the immunocompromised setting is the key reason for this choice.